PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportspostherpetic neuralgia
MeSH D051474 - postherpetic neuralgia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D009437:Neuralgia
$
Success rate
D051474: 
Postherpetic neuralgia
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaGabapentin Gabapentin  2004-10-08   
Pregabalin Pregabalin  2019-07-19   
Taro PharmaceuticalGabapentin Gabapentin  2013-07-03   
Glenmark PharmaceuticalsGabapentin Gabapentin  2006-08-18   
MylanGabapentin Gabapentin  2011-02-14   
Pregabalin Pregabalin  2019-09-20   
Pregabalin Pregabalin Mylan  2015-06-24   
Pregabalin Pregabalin Mylan Pharma  2015-06-25   
CiplaGabapentin Gabapentin  2009-12-30   
Pregabalin Pregabalin  2019-07-19   
Lupin ResearchGabapentin Gabapentin  2018-08-24   
Pregabalin Pregabalin  2022-05-03   
SandozGabapentin Gabapentin  2006-01-24   
Pregabalin Pregabalin Sandoz  2015-06-19   
Pregabalin Pregabalin Sandoz GmbH  2015-06-19   
Aurobindo PharmaGabapentin Gabapentin  2008-01-31   
Pregabalin Pregabalin  2023-03-29   
Dr Reddys LaboratoriesPregabalin Pregabalin  2019-07-19   
Rising PharmaceuticalsPregabalin Pregabalin  2019-07-19   
Gabapentin Gabapentin  2017-03-24   
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
78%
7/9
Phase 2
55%
16/29
Phase 3
57%
8/14
Approved: 3Overall Success rate: 25%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Mylan
1
2
3
4
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use